Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the "**Company**", together with its subsidiaries, the "**Group**") proposed the election of Ms. Wang Zhiyao (王智瑤女士) ("**Ms. Wang**") as the independent non-executive director of the eleventh session of the Board, to fill the vacancy resulting from the upcoming retirement of Mr. Tian Qiusheng (田秋生先生) and Mr. Wong Kam Wa (黃錦華先生) as the independent non-executive directors of the Company due to the expiration of their 6-year term of office as directors. The independent non-executive directors have also expressed an independent opinion approving the qualifications of Ms. Wang.

The proposed appointment of Ms. Wang as the independent non-executive director of the Company, is subject to the approval of the shareholders of the Company at the 2025 first extraordinary general meeting of the Company (the "**EGM**"). The qualification and independence of Ms. Wang are subject to the filing and review of the Shenzhen Stock Exchange without objection before putting forward to the EGM for voting.

The term for Ms. Wang's appointment as the independent non-executive director of the eleventh session of the Board shall commence from the date of the EGM in which her appointment is approved and end on the expiry of the term of the eleventh session of the Board. The Company will enter into service agreement with Ms. Wang upon the approval of the appointment at the EGM.

The biography of Ms. Wang is as follows:

Ms. Wang, aged 39, holds a Bachelor of Clinical Medicine from Xi'an Jiaotong University, a Master of Public Administration from Renmin University of China, and a Master of Finance from Harvard University. She has previously worked at the Chinese Academy of Medical Sciences Institute of Tissue Engineering Research Center (中國醫學科學院組織工程研究中心), Sanofi China R&D Center, and Novartis Global

R&D Headquarters. From October 2014 to October 2018, she was the Founder and CEO of Suzhou Yihaoxian Pharmaceutical Technology Co., Ltd (蘇州醫號線醫藥科技有限公司). From October 2018 to December 2022, she held the position of Founding General Manager and Chief Operating Officer at BioShin Limited. From January 2023 to August 2024, she served as Managing Partner at Avenex Biosciences Limited. Since September 2024, she has been pursuing a Doctor of Philosophy in Biomedical Sciences at The University of Hong Kong.

As at the date of this announcement, Ms. Wang has confirmed that she has met the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**"). Save as disclosed in this announcement, Ms. Wang (i) has not held any directorship in other listed companies in the present and last three years preceding the date of this announcement; (ii) does not hold any other positions in the Group; (iii) does not have any relationship with any other directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company, and (iv) does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Upon the appointment, Ms. Wang will be entitled to an annual director fee of RMB120,000 (before tax). Such fee is determined with reference to the duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for such positions.

Save as disclosed above, there are no other matters needed to be brought to the attention of the shareholders of the Company in relation to the proposed appointment of Ms. Wang as the independent non-executive director of the Company and there is no other information required to be disclosed pursuant to any of the provisions of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

By order of the Board
Livzon Pharmaceutical Group Inc. *
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
10 November 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

* *For identification purpose only*